Fujifilm to spend $5bn to become global contract drugmaker

Opportunity seen in outsourcing trend similar to chip industry

20211115 Fujifilm

Fujifilm plans to introduce a new production system that can produce antibodies with high purity more efficiently at its plant in the U.K. (Photo courtesy of Fujifilm)

TSUYOSHI TAMEHIRO and ARATA SHIGENO, Nikkei staff writers

TOKYO -- Fujifilm Holdings is staking its future on becoming a provider of drug development and manufacturing services to other pharmaceutical companies.

The Japanese company is spending 600 billion yen ($5.25 billion) to gain a foothold in a market that is expected to grow rapidly in the coming years. It decided at the end of June to increase its investment by 90 billion yen, betting that it can become the pharmaceutical industry's answer to Taiwan Semiconductor Manufacturing Co., which specializes in making computer chips designed by others.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.